MVA-BN WEV / Bavarian Nordic - LARVOL DELTA

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine (clinicaltrials.gov) - P2 | N=411 | Active, not recruiting | Sponsor: Bavarian Nordic | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine (clinicaltrials.gov) - P2 | N=400 | Active, not recruiting | Sponsor: Bavarian Nordic | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Bavarian Nordic | Active, not recruiting ➔ Recruiting

Enrollment open • CNS Disorders

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Bavarian Nordic

New P2 trial • CNS Disorders

Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study. (PubMed, Lancet Microbe) - P2 | "CHIKV VLP vaccine was well tolerated and similarly immunogenic in both alphavirus vaccine-naive participants and previous recipients of a heterologous alphavirus vaccine. There were no significant differences in adverse events between the groups. The results of this study support the use of CHIKV VLP vaccine in individuals with previous alphavirus vaccine exposure."

Journal • P2 data • Chikungunya • CNS Disorders

Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial. (PubMed, Vaccine) - P1 | "The study demonstrated that MVA-BN-WEV is well tolerated, induces immune responses, and is suitable for further development."

Journal • P1 data • CNS Disorders • Fatigue • Musculoskeletal Pain • Pain • Respiratory Diseases

MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques. (PubMed, NPJ Vaccines) - "MVA-based monovalent eastern equine encephalitis virus (MVA-BN-EEEV) and multivalent western, eastern, and Venezuelan equine encephalitis virus (MVA-BN-WEV) vaccines were evaluated in the cynomolgus macaque aerosol model of EEEV infection...Complete protection from viremia was afforded by both vaccines, with near complete protection from vRNA loads in tissues and any pathologic evidence of central nervous system damage. Overall, the results indicate both vaccines are effective in eliciting an immune response that is consistent with protection from aerosolized EEEV-induced disease."

Journal • CNS Disorders • Infectious Disease

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=45; Completed; Sponsor: Bavarian Nordic; Active, not recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders